SAN DIEGO, Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that its Target Selector™ assays are now
available to physicians in order to evaluate the cerebrospinal
fluid (CSF) of their patients for the presence of circulating tumor
cells (CTCs) and biomarkers for patients with breast or lung cancer
suspected of brain or central nervous system (CNS) metastases. The
presence of tumor cells in CSF may be an indicator of brain
metastases, which occurs when cancer has spread into the CNS. Up to
30% and 36% of patients diagnosed with breast and lung cancer,
respectively, will develop brain metastases.
"Testing the CSF for cancer biomarkers in patients suspected to
have brain metastases can be important, as the rapid confirmation
and characterization of CNS involvement enables appropriate
treatment selection in a timely manner," stated Santosh Kesari, MD, PhD, Chair and Professor,
Department of Translational Neurosciences and Neurotherapeutics,
Director of Neuro-oncology at the Pacific Neuroscience Institute
and John Wayne Cancer Institute. "Liquid biopsy tests offer
the ability to analyze an additional specimen type, beyond blood,
to help physicians identify biomarkers and hence inform clinical
decision making."
"We are very pleased to make our Target Selector™ platform
available for testing CSF, as a more rapid identification of
molecular alterations in brain metastases can aid physicians in
choosing the best treatment options for their patients with breast
or lung cancer," said Michael W.
Nall, Biocept's President and CEO. "Among the significant
capabilities of our technology is its versatility, which enables
applications in a variety of clinical situations and for use with
multiple types of biofluids."
About CSF Testing
A medical procedure known as a spinal tap or lumbar puncture is
typically done to collect CSF when cancer patients present with CNS
symptoms, for example confusion or dementia. Over 200,000 of these
procedures are performed annually in the U.S. Biocept's Target
Selector™ testing provides an alternative and potentially more
accurate means compared to cytology to evaluate CSF. For more
information about Biocept's Target Selector™ testing, please
contact Biocept Customer Services at 888.332.7729.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both CTCs and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer and the potential
clinical utility of our proprietary technology platform as
applied to CSF, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
http://www.sec.gov/.
Contacts
Investors:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR
Jules
Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-announces-validation-and-availability-of-its-liquid-biopsy-platform-for-the-detection-of-actionable-cancer-biomarkers-in-cerebrospinal-fluid-300985044.html
SOURCE Biocept, Inc.